Other VEGF multi-kinase inhibitors have been evaluated in recurrent GBM, such as sunitinib, sorafenib, ponatinib, and vandetanib, and all showed minimal or absent activity or raised major concerns for serious adverse events [81•]. The gene discussed is VEGFA; the disease is glioblastoma.